CD46 and Miyoshi myopathy: A phase I clinical trial for CD46–ADC (FOR46, Fortis Therapeutics) is now complete in patients with relapsed or refractory MM (NCT03650491), showing single-agent activity with partial response or better observed in approximately one-third of patients [30].